

NDMA as an Impurity of Ranitidine: A Carcinogenic Moiety

Amandeep Singh*, Aseem Setia and Gupta GD

*Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab-142001, India.

Received April 10, 2021; Revised May 02, 2021; Accepted May 05, 2021

INTRODUCTION

Ranitidine, an H₂-receptor antagonist, is widely used to treat gastroesophageal reflux disease (GERD). It is also used to treat peptic ulcer disease, hypersecretory states such as Zollinger-Ellison syndrome, systemic mastocytosis, and the prevention of stress ulcers and gastrointestinal bleeding [1]. It was approved for use in the United States in 1983, and by 1988, it had become the best-selling drug on the planet. Ranitidine was approved for over-the-counter use in 2004 and was previously marketed under the brand name Zantac [2]. In September 2019, a petition was submitted to the US Food and Drug Administration (FDA) stating that routine testing had revealed N-nitrosodimethylamine (NDMA), a likely human carcinogen, in Zantac, a brand name for ranitidine. NDMA is classified as a probable human carcinogen, which means it has the potential to cause cancer. It is a known environmental contaminant that can be found in water as well as foods such as meat, dairy products, and vegetables [3]. N-nitrosodimethylamine (NDMA) is a chemical that has been shown to cause tumors in the gastrointestinal tract, liver, lungs, and kidneys. NDMA directly activates RAS oncogenes, and its methylated metabolite, methyl diazonium, is also a mutagen. NDMA has been classified as a probable carcinogen by international organizations ranging from the Environmental Protection Agency to the World Health Organization's International Agency for Research on Cancer [4]. On September 13, 2019, the FDA issued a warning to consumers that some ranitidine products contain unacceptable levels of NDMA and are being recalled. Because of the high levels of NDMA, many manufacturers, including Apotex Corporation, Sandoz, Sanofi, Aurobindo, and Dr Reddy Labs, have had to recall products containing ranitidine. The FDA announced in April 2020 that ranitidine would be withdrawn from the market and advised consumers to stop using the product. Ranitidine is the second medication linked to NDMA impurities. The first was the therapeutic class known as Angiotensin II Receptor Blockers (ARBs), which were found to contain NDMA and other nitrosamines in 2018. The published NDMA levels detected in ranitidine are lower on average than in ARBs, and detection necessitates the use of highly accurate and sensitive

methods [5]. The Valisure pharmacy reported in 2019 that ranitidine (the over-the-counter brand Zantac) used to treat gastric hyperacidity and reflux contained unsafe levels of NDMA [6]. According to their findings, the spontaneous breakdown of the ranitidine molecule could produce dimethylamine and nitrites, resulting in the formation of NDMA. The acceptable daily intake limit for NDMA was set by the FDA at 0.096 micrograms or 0.32 ppm for ranitidine. However, NDMA levels in ranitidine products were found to be up to nine times higher than the FDA's recommended limit. As a result, many manufacturers and retailers have completely recalled ranitidine around the world [7]. Liquid Chromatography-Mass Spectrometry (LC-MS) and Liquid Chromatography High-Resolution Mass Spectrometry (LC-HRMS) are two published analytical methods for NDMA analysis in ranitidine (LC-HRMS). A third-party laboratory also used Gas Chromatography-Mass Spectrometry (GC-MS) to detect NDMA concentrations in ranitidine samples [5]. According to the FDA, the high temperature (266°F) gas chromatography/mass spectrophotometry method used in Valisure's laboratory is unsuitable because heating the sample produces NDMA. The FDA's preferred method, liquid chromatography-high-resolution mass spectrometry, does not use heating, and while it discovered significantly lower NDMA doses per tablet for ranitidine, it still discovered unacceptable doses [6].

The current study's positive association between ranitidine and pancreatic cancer was consistent with the findings of Habel [8] who found a statistically significant 2.6-fold increased risk associated with ranitidine use for the combined outcome of stomach/esophageal cancer [8,9]. Discovered a statistical link between occupational NDMA exposure and

Corresponding author: Amandeep Singh, Department of Pharmaceutics ISF College of Pharmacy, Moga-142001, Punjab, India, Tel: +91-9465423413; E-mail: ad4singh@gmail.com

Citation: Singh A, Setia A & Gupta GD. (2021) NDMA as an Impurity of Ranitidine: A Carcinogenic Moiety. *Int J Anaesth Res*, 4(3): 165-166.

Copyright: ©2021 Singh A, Setia A & Gupta GD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

pancreatic cancer deaths [9,10] reported site-specific results for the proximal and distal colon and rectum in their study of NDMA and colorectal cancer [10]. The findings revealed a statistically significant link between dietary NDMA exposure and rectal cancer. The FDA has acted appropriately thus far, but there may be more that can be done to improve our understanding of this issue and limit human exposure to NDMA through prescription drugs. Current ranitidine users were found to have a significantly increased risk of ductal carcinoma, but neither cimetidine nor famotidine were. While these studies are far from conclusive, there are less risky options.

REFERENCES

1. Wagner JA, Colombo JM (2020) Medicine and Media: The Ranitidine Debate. *Clin Transl Sci* 13(4): 649-651.
2. Tabatabaiefar MA, Moridnia A (2017) Gastrointestinal Cancers. *Cancer Genetics and Psychotherapy*. pp: 589-625.
3. Mahase E (2019) FDA Recalls Ranitidine Medicines over Potential Cancer-Causing Impurity. *BMJ* 367: 15832.
4. White CM (2020) Understanding and Preventing (N-Nitrosodimethylamine) NDMA Contamination of Medications. *Ann Pharmacother* 54(6): 611-614.
5. Yahya AM, Alghamdi TS, Aldawsari FS (2020) HS-SPME-GC-MS as an Alternative Method for NDMA Analysis in Ranitidine Products. *J Pharm Biomed Anal* 191: 113582.
6. Park L L C Science, New Haven (2019). Valisure, LLC. 5 Science Park, New Haven, CT 06511, 833-825-4787, www.valisure.com." 20852: 1-19.
7. El-Shaheny R, Mohamed R, Koji Y, El-Maghrabey M (2019) Estimation of Nizatidine Gastric Nitrosatability and Product Toxicity via an Integrated Approach Combining HILIC, in Silico Toxicology, and Molecular Docking. *J Food Drug Anal* 27(4): 915-925.
8. Habel LA, Theodore RL, Gary DF (2000) Cimetidine Use and Risk of Breast, Prostate, and Other Cancers. *Pharmacoepidemiol Drug Saf* 9(2): 149-155.
9. Hidajat M, McElvenny DM, Ritchie P, Darnton A, Mueller W, et al. (2019) Lifetime Exposure to Rubber Dusts, Fumes and N-Nitrosamines and Cancer Mortality in a Cohort of British Rubber Workers with 49 Years Follow-Up. *Occup Environ Med* 76(4): 250-258.
10. Zhu Y, Wang PP, Zhao J, Green R, Sun Z, et al. (2014) Dietary N-Nitroso Compounds and Risk of Colorectal Cancer: A Case-Control Study in Newfoundland and Labrador and Ontario, Canada. *Br J Nutr* 111(6): 1109-1117.